Conference Coverage
Conference Coverage
Lenalidomide maintenance after transplant improves OS in MM
the ASCO Annual Meeting © ASCO/Todd Buchanan CHICAGO—Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT...
Conference Coverage
Better ways to drive CAR T-cell therapy
© ASCO/Brian Powers CHICAGO—Treatment dose and schedule, as well as a patient’s tumor burden, influence the outcome of therapy with chimeric...
Conference Coverage
‘Impressive’ responses with nivolumab in relapsed Hodgkin lymphoma
Key clinical point:.
Conference Coverage
Genetic therapy lowers joint bleeding in hemophilia B
COPENHAGEN – It’s early days yet, but results look highly promising for the ability of an experimental gene-transfer therapy to improve...
Conference Coverage
No kidding: Adults fare better with pediatric ALL regimen
COPENHAGEN – Young adults with acute lymphoblastic leukemia do better when they are treated like children – that is, with a standard pediatric...
Conference Coverage
Statins improve ovarian cancer survival
SAN DIEGO – The risk of all-cause mortality in ovarian cancer patients on statin therapy was reduced by one-third.
Conference Coverage
Heat shock protein peptide vaccine appears safe, effective for glioblastoma patients
Key clinical point: A heat shock protein peptide vaccine appears safe and effective for patients with glioblastoma in an early stage trial. Major...
Conference Coverage
ESA benefits lower-risk MDS patients
COPENHAGEN—The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic...
Conference Coverage
Immunotherapy ‘outcompetes’ chemo in rel/ref B-ALL
COPENHAGEN—Interim results from the phase 3 TOWER trial suggest blinatumomab can prolong overall survival (OS) when compared to standard care in...
Conference Coverage
Hold that TKI – When it’s safe to stop in CML
Key clinical point:.Tyrosine kinase inhibitor therapy can be safely stopped and resumed in many patients with chronic-phase chronic myeloid...
Conference Coverage
Daratumumab plus len-dex stalls myeloma progression in POLLUX trial
The anti-CD38 monoclonal antibody daratumumab added to lenalidomide/dexamethasone improved progression-free survival in relapsed/refractory...